🎀 GYN Oncology — 2026-W44

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

International expert consensus update on low-grade serous ovarian cancer, published in Gynecologic Oncology. Updates recommendations on frontline and recurrent systemic therapy, including chemotherapy, endocrine therapy and MAPK-targeted combinations, shaping management of this rare disease.

Single-arm phase 2 of carboplatin plus mirvetuximab soravtansine in FRα-expressing recurrent platinum-sensitive ovarian cancer, published in Clinical Cancer Research. Shows high, durable responses with manageable ocular toxicity and notable pneumonitis, supporting the combination as a promising option pending randomized data.

Retrospective single-institution cohort of gynecologic cancer patients on immune checkpoint inhibitors, published in Gynecologic Oncology. Characterizes VTE incidence, risk factors and clinical impact, informing vigilance and thromboprophylaxis awareness during immunotherapy.

Narrative review in endometrial cancer, published in Clinical Epigenetics. Summarizes epigenetic alterations and the established immunotherapy landscape in advanced/recurrent disease, plus investigational epigenetic agents that may enhance checkpoint blockade sensitivity.

Translational single-nucleus profiling study of longitudinal biopsies in high-grade serous ovarian cancer, published in Cancer Discovery. Suggests chemoresistant states are epigenetically primed before therapy, but it is hypothesis-generating with no immediate treatment implications.

Single-institution retrospective cohort of gynecologic cancer patients (mostly endometrial, cervical, ovarian) with severe immune-related adverse events needing steroids, published in Gynecologic Oncology. Suggests that following NCCN-concordant, longer steroid tapers is associated with less need for additional immunosuppression, informing irAE management.

Translational proteomic and imaging study in advanced or recurrent MMRd endometrial cancer treated with checkpoint inhibitors, published in J Immunother Cancer. Suggests collagen remodeling is associated with ICI resistance and may help predict response, but needs further validation before it can guide practice.

Cross-sectional international survey of gynecologic oncology providers on BRCA and HRD testing in ovarian cancer, published in Int J Gynecol Cancer. Shows variable testing implementation, highlighting gaps (especially early-stage) that could inform efforts to standardize biomarker testing for PARP inhibitor selection.

Open-label single-arm phase 2 of cabozantinib monotherapy in recurrent or metastatic cervical cancer after platinum chemotherapy, published in Gynecologic Oncology. Shows modest activity with notable fistula/perforation and toxicity, so it is an incremental option with limited practice impact.

Retrospective multi-institution cohort of patients with recurrent endometrial cancer treated with lenvatinib plus pembrolizumab, published in Journal of Gynecologic Oncology. Suggests a longer platinum-free interval is associated with better outcomes on this regimen, which may inform expectations and sequencing, though evidence is limited by its retrospective design.

Development and multi-cohort validation of a deep learning model predicting HRD from pathology slides in high-grade serous ovarian cancer, published in Nature Communications. May offer an accessible alternative to genomic HRD testing for treatment stratification, but clinical outcome benefit is not shown.